IDSA GUIDELINES Bundle (free trial)

Community-Acquired Pneumonia

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/53989

Contents of this Issue

Navigation

Page 10 of 11

Table 5. Antimicrobials for Treatment of CAP— Antimicrobial (Brand) Penicillins Amoxicillin (Amoxil ® Nafcillin (Unipen® Oxacillin (Bactocill ® , others) , others) i.v. , others) Penicillin G i.v. (aqueous) Miscellaneous Aztreonam (Azactam® ) Clindamycin (Cleocin® Doxycycline (Vibramycin® Linezolid (Zyvox® ) Vancomycin (Vancocin® i.v. 15 mg/kg q12h , others) i.v., i.m. 1-2 g q8-12h (moderately severe infection) 2 g q6-8h (severe, life- threatening infection) , others) , others) i.v., i.m. p.o. i.v. p.o. 600 mg q8h 150-450 mg q6-8h 200 mg i.v. day 1 in 1-2 doses, then 100 mg q12h 100 mg q12h i.v., p.o. 600 mg q12h > Clindamycin active against S. pneumoniae but not active against H. influenzae or atypical pathogens > Doxycycline active against strains of S. pneumoniae, H. influenzae, and atypical pathogens; generally well tolerated > Linezolid active against most Gram-positive bacteria including multidrug-resistant S. pneumoniae and S. aureus but lacks established activity against atypical pathogens * Dose recommended in IDSA/ATS GUIDELINES (2007). • See product labeling for complete prescribing information. NOTE. Choices should be modified on the basis of susceptibility test results and advice from local specialists. Refer to local references for appropriate doses. 4-24 million units/d (moderate-high dose) in divided doses q4-6h 1-2 g q4-6h p.o. 500 mg q8h OR 875 mg q12h 1 g tid* i.v. 1-2 g q4-6h > Amoxicillin preferred for p.o. treatment of susceptible strains of S. pneumoniae, but high doses required; lacks activity against atypical pathogens and β-lactamase producers > Penicillin G active against penicillin-susceptible strains of S. pneumoniae, but limited against other common pulmonary pathogens Dosage Form Adult Dose Comments continued

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Community-Acquired Pneumonia